Inhaled and Nasal Nano-formulations for Targeting Tuberculosis Therapy
Verma R, Sudhakar J, Singh A.
RDD Asia 2024. Volume 1, 2024: 38-45.
Abstract:
Central nervous system tuberculosis (CNS-TB) is an extra-pulmonary form of tuberculosis (TB) that occurs when Mycobacterium tuberculosis (MTB) spreads to the cerebrospinal fluid (CSF) and meninges. Nasal delivery of hybrid nano- and micro-systems presents a promising strategy for targeting TB in both the brain and lungs. This study focuses on enhancing anti-TB therapy by encapsulating rifampicin in PLGA-based nano-in-microparticles (RIF-NIM) for intranasal administration. RIF-NIM was found to improve rifampicin brain permeation, achieving therapeutic levels. In a murine CNS-TB model, intranasal RIF-NIM reduced mycobacterial burden in both the brain and lungs, supporting its potential for CNS-TB treatment.
I have a subscription
Log in for instant access.
I do not have a subscription
Purchase Article (in PDF format)
